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Oleyl 2-acetamido-2-deoxy-a-D-glucopyranoside (1) was previously shown to exhibit antimitotic
activity on glioma (C6) and melanoma (A375) cell lines. Preliminary studies about its mechanism
of action using 1H MAS NMR suggested that 1 may be altering the metabolism of lipids.
We have now studied the eﬀect of 1 on the fatty acid, sphingolipid and ganglioside content in a
line of carcinomic human alveolar epithelial cells (A549) using UPLC-MS. Oleic acid and
NB-DNJ were used as positive controls for inhibition of fatty acid and ganglioside synthesis,
respectively. Compound 1 (10 mM) was more eﬃcient than oleic acid in reducing fatty acid levels
of A549 cells, producing a decrease in the range of 40–15%, depending on the acyl chain length
and the number of insaturations. In addition, glycoside 1 caused a reduction on ganglioside
content of A549 tumor cell line and accumulation of lactosylceramide, the common metabolic
precursor for ganglioside biosynthesis. Alteration of ganglioside metabolism was also observed
with two galactosylated derivatives of 1, which caused a more pronounced increase in
lactosylceramide levels. Compound 1 at higher concentrations (above 30 mM) produced drastic
alterations in glycosphingolipid metabolism, leading to cell metabolic proﬁles very diﬀerent from
those obtained at 10 mM. These biochemical changes were ascribed to activation of endoplasmic
reticulum stress pathways.
1. Introduction
Lung cancer is the leading cause of cancer-related human
deaths. One of every three cancer-related deaths is attributable
to lung cancer with an overall 5-year survival of o15%.1,2
Non-small cell lung cancer accounts for 80% of all lung
cancers, including squamous cell carcinomas, adenocarcinomas,
and large cell carcinomas.3,4 Therefore, the exploration and
development of more eﬀective chemotherapeutic agents that
can target the molecules associated with tumor proliferation,
angiogenesis, and apoptosis resistance will lead to improved
outcomes for lung cancer patients.
Sphingolipids (SLs) are a family of lipids that play essential
roles in cell signalling. From a structural standpoint, SLs
derive from sphingosine (Sph), a long chain amino alcohol,
that is acylated with a long chain fatty acid to give ceramides
(Cer), the central core of glycosphingolipids (GSLs) and
sphingomyelin (SM) (Scheme 1). Living cells contain several Cer
and Cer metabolite species diﬀering in the length and degree of
unsaturation of their acyl chain, which appears relevant for their
biological activities. Moreover, abnormal SLs metabolism is
known to occur in some diseases, such as, certain sphingolipidoses,
cancer, diabetes and atherosclerosis.5 Gangliosides, a class of sialic
acid containing glycosphingolipids, have crucial regulatory roles in
tumor formation and progression.6–8 Abnormal ganglioside
expression is associated with the malignancy of cancer cells9 and
ganglioside content is upregulated in some metastasizing tumor
cells, such as lymphoma, ﬁbrosarcoma, and melanoma.10–12
The ﬁrst step in the biosynthesis of glycosphingolipids is the
glycosidation of the lipid ceramide leading to glucosylceramide
(GlcCer), and further glycosylation steps leads to complex
gangliosides (Scheme 1). Inhibition of the enzyme GlcCer
synthase causes a tumorigenicity reduction of transformed cells,
mainly due to a decrease in ganglioside levels.7 The imino-sugar
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N-butyl-deoxynojirimicin (NB-DNJ) (see Chart 1) inhibited
melanoma tumor growth by inhibiting GlcCer synthase.13
We recently synthesized a new family of glycolipids with
antimitotic activity for cultured glioma and melanoma cells.14
The results indicated that the presence of an oleyl residue
linked to the glucosamine backbone increased the inhibitory
activity, the oleyl glycoside 1 being the most inhibitory
compound (Chart 1). Regarding potential use of 1 for
the treatment of brain tumors, we recently reported15,16 the
preparation of glycopolymers carrying 1 and their eﬀect on
cultured glioma cells. Preliminary studies17 on the mechanism
of growth inhibition by 1 using proton magic angle spinning
(MAS) NMR, suggested that the compound may be inhibiting
the synthesis of tumor fatty acids, probably due to the
presence of the oleyl moiety in its structure. In this sense,
similar metabolite changes were observed after 24 h incubation
of C6 rat glioma cells with 1 or with oleic acid (Chart 1), an
inhibitor of fatty acid and cholesterol synthesis.18 Fatty acid
biosynthesis is upregulated in tumoral cells19 and has been
proposed as a new target for cancer treatment.20
The chemical structure of 1 resembles that of GlcCer and
their lipid precursors (Scheme 1), and therefore, it seemed
reasonable to think that 1 could additionally alter sphingolipid
and ganglioside biosynthesis in tumoral cells. Here we present
the results of evaluating 1 as inhibitor of GlcCer and SM
synthases and the eﬀect on the fatty acids content and
sphingolipidome of a human alveolar epithelial cells carcinoma
line (A549). We examined also the eﬀect of treatment with 1
and with two galactosylated derivatives on the ganglioside
content of A549 cells.
2. Results and discussion
2.1 Eﬀect of 1 on sphingomyelin and GlcCer synthase activity
and sphingolipid content
Glycoside 1 inhibited A549 cell proliferation with an IC50 of
20 mM, a value in the concentration range of those obtained14
for rat C6 glioma (IC50, 1.3 mM), human U373 glioma (IC50,
4.3 mM) and A375 melanoma (IC50, 4.8 mM) lines. Compound
1 was previously shown to be more cytotoxic for tumor cells
than for normal cells.14,15
For the evaluation of the activity of 1 as inhibitor of SM and
GlcCer synthases, A549 cell lysates were used as source of
enzymes and ﬂuorescent Cer-C6-NBD as substrate. For
GlcCer synthase inhibitory activity, the iminosugar NB-DNJ
was used as positive control.13 Glycoside 1 was inactive
against SM and GlcCer synthases, even at a concentration
of 250 mM (Fig. 1). On the other hand, NB-DNJ inhibited
GlcCer synthase activity by 65% at 10 mM concentration,
without aﬀecting SM synthase.
To evaluate the eﬀect of glycoside 1 on the sphingolipidome
of A549 cells, compound 1 (10 mM) was incubated
with the cells for 48 h and then lipids were extracted and
analyzed by UPLC-MS, as described in the experimental
Scheme 1 Sphingolipid and ganglioside biosynthesis. GalT-1, galacto-
syltransferase; Gal, galactose; GalNAc, N-acetylgalactosamine; Glc,
glucose; SA, sialic acid.
Chart 1 Chemical structures of glycoside 1, NB-DNJ and oleic acid.
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section. For comparison, A549 cells were also cultured in
the presence of 10 mM oleic acid, 50 mM NB-DNJ or vehicle
(control).
Among the various sphingolipids present in cells, we
focused initially on the Cer and SM content. While no eﬀect
was observed with NB-DNJ, the exposure of A549 cells
to 1 caused a reduction in the content of both sphingolipids,
compared to untreated cells (Fig. 2). Ceramide and sphingomyelin
content was reduced 26 and 31%, respectively, the species
with C24 acyl chain being that most aﬀected (see ESIw).
Oleic acid also caused a reduction on ceramides and
sphingomyelins, although to a lesser extent than 1. Concerning
the eﬀect on GlcCer content, the treatment with NB-DNJ
(50 mM) markedly reduced the GlcCer concentration
in the cells, with a total decrease of 65% (Fig. 2). This
result is in agreement with previous studies with other cell
types,13 and can be ascribed to partial inhibition of GlcCer
synthase activity by NB-DNJ. The GlcCer content of cells
treated with compound 1 and oleic acid was also reduced,
although the eﬀect was less intense than that with NB-DNJ
(Fig. 2).
2.2 Eﬀect of 1 on fatty acid content
Because glycoside 1 is not an inhibitor of the enzymes directly
involved in SM and GlcCer biosynthesis, the reduction of
these sphingolipids must be related to a decline in the levels of
their lipid precursors. As mentioned in the introduction,
preliminary studies indicate that glycoside 1 altered lipid
metabolism, probably through the inhibition of fatty acid
synthesis.17 To conﬁrm this mode of action, fatty acid content
was analyzed in cells treated with 1 and with oleic acid, a
known inhibitor of fatty acid synthesis.18 As shown in Fig. 3,
compound 1 was more eﬀective than oleic acid in reducing
fatty acid levels. When the cells were treated with compound 1,
a decrease in the range of 15–40%, depending on the acyl
chain length and the number of insaturations present, was
observed. The decrease in fatty acid content was of the same
order as for sphingomyelin and glucosylceramide levels and
therefore could account for the drop in the content of those
sphingolipids.
2.3 Eﬀect of 1 on lactosylceramide and ganglioside content
Interesting results were obtained when contents of lactosyl-
ceramide (LacCer) and gangliosides were analyzed. As
expected,13 NB-DNJ (50 mM) reduced the content of all
detected glycosphingolipids (Fig. 4), whereas oleic acid had
no eﬀect (results not shown). In contrast, exposure of A549 cells
to glycoside 1 (10 mM) caused a rise (40%) in lactosylceramide
and a marked decrease, taking into account that it was used at
a 5-fold lower concentration than NB-DNJ, in the levels of all
detected gangliosides (around 20%, Fig. 4). Considering the
biosynthetic pathway of gangliosides (Scheme 1), these results
Fig. 1 The eﬀect of compound 1 on sphingomyelin (SM) and
glucosylceramide (GlcCer) synthase activity. HPLC-FD proﬁle of
ﬂuorescent sphingolipids produced from Cer-C6-NBD in A549 cell
lysates, incubated with NB-DNJ (10 mM), compound 1 (250 mM) or
ethanol (1 mL), as described in the experimental section. These
chromatograms are representative of three diﬀerent experiments
performed in duplicate.
Fig. 2 Eﬀect of 1, NB-DNJ and oleic acid on ceramide (Cer),
sphingomyelin (SM) and glucosylceramide (GlcCer) content of A549
carcinoma cells. Data were normalized to the same number of cells
(1  106 cells). The content in pmol per 1  106 cells for the control
was: 214  43; 3127  277 and 153  16 for Cer, SM and GlcCer
respectively. A549 cells were seeded at 250 000 cells per well in 6-well
plates. The medium was renewed after 24 h and cells were cultured in
medium containing 10% FBS, in the presence of compound 1 (10 mM),
NB-DNJ (50 mM), oleic acid (10 mM) or ethanol (1 mL). Two days
later, the cells were extracted and analyzed as described in the
experimental section. The data are the mean of two experiments
performed by triplicate. The diagram includes the ANOVA results
for each treatment with respect to control at a signiﬁcance level of:
*p o 0.05; **p o 0.01.
Fig. 3 Eﬀect of compound 1 on fatty acid production. Black bars:
A549 cells treated with 1 (10 mM); empty bars: A549 cells treated with
oleic acid (10 mM). The diagram includes the ANOVA results for each
treatment with respect to control at a signiﬁcance level of: *po 0.05;
**p o 0.01; ***p o 0.001.
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suggest that glycoside 1 partially inhibited biosynthesis at the
step of GM3 formation, leading to lower ganglioside levels
and the accumulation of LacCer. The possibility that 1 acted
as an inhibitor of GM3 synthase could have implications for
its chemotherapeutic potential. A recent paper21 described
GM3 synthase as a therapeutic target in cancer, the silencing
of this enzyme signiﬁcantly inhibiting cell migration, invasion
and anchorage-independent growth in vitro, as well as lung
metastasis in vivo. Besides, GM3 is the simplest ganglioside
oligosaccharide and serves as a precursor for most of the more
complex gangliosides.
To further check the generality of ganglioside depletion by
treatment with 1, we tested the eﬀect of the compound on the
ganglioside content of other transformed cell lines where 1
had shown antimitotic activity,14 i.e. C6 glioma and A375
melanoma cell lines. The cells were cultured in the absence
(control) or the presence of 1 (10 mM) for 48 (A375 cells) or
96 h (C6 cells). After this time, gangliosides were extracted and
analyzed by HPLC. Based on the elution times of standard
gangliosides, and after mass spectrometric analysis of the
eluted fractions, the main gangliosides detected in C6 and
A375 cell extracts were identiﬁed as GM3, GM2, GM1 and
GD3. The relative amounts of each ganglioside in compound
1-treated cells were compared to controls (Fig. 5). We
observed a decrease in all the gangliosides in both C6 and
A375 cells (45 and 20% total ganglioside reduction with
respect to control for C6 and A373 cells, respectively). This
general ganglioside depletion conﬁrms that 1must be acting at
a step in the biosynthetic pathway prior to the formation of
the simplest ganglioside GM3.
2.4 Exposure of tumor cells to higher concentrations of 1
The eﬀect of 1 on lipid and ganglioside content was evaluated
at higher concentrations. Incubation of A549 cells with com-
pound 1 at 50 mM led to almost total cell death as observed by
the small number of adhering (viable) cells after washing
(Fig. 6). A signiﬁcant ratio of cell death was also observed
at 30 mM of 1; the analysis of lipid extracts after treatment
with this concentration showed values for sphingolipid and
ganglioside levels which are very diﬀerent from those obtained
at 10 mM concentration. As shown in Fig. 7, a signiﬁcant
increase of Cer, GlcCer and LacCer levels was observed in
30 mM 1-treated cells with respect to the control. These results
point out that, at concentrations of 30–50 mM, compound 1
caused drastic alterations in the lipid metabolism of A549 cells
(some values of sphingolipid and ganglioside levels reversed as
compared to those obtained at 10 mM), and leads eventually to
cell death. These results are in line with our previous ﬁndings
in C6 cells,17 which indicated that above a certain concentra-
tion range (440–50 mM), compound 1 causes apoptosis in C6
glioma cells as evidenced by the analysis of DNA-fragmentation.
In this cell line, we have now performed preliminary experi-
ments to ﬁnd the mechanism by which apoptosis is induced.
Recently, lipid metabolism has been related to endoplasmic
reticulum (ER) stress response pathways and to apoptosis
induction. To evaluate whether treatment with compound 1
induce these pathways, we used two reporters, one for the
IRE1-XBP1 (inositol-requiring kinase 1) branch pathway
(5xUPRE-pGL3) and a second one for the ATF6 (activating
transcription factor 6) pathway (ERSE-pGL3) (Fig. 8). As a
negative control a related compound previously reported by
us,22 octyl 6-O-pentaerythrityl-N-acetyl-a-D-glucosaminide
(OPG), that was less antimitotic and did not induce apoptosis,
was evaluated. As shown in Fig. 8, this compound did not
induce any of the two branches. However, treatment of C6
with compound 1 at concentrations ranging from 25 to 100 mM
induced ER stress response. Surprisingly, this induction was
speciﬁc for the IRE1-XBP1 branch pathway (5xUPRE-pGL3),
but not for the ATF6 pathways (ERSE-pGL3). Although this
is a preliminary study and we have not tested other ER stress
pathways (like ATF4 pathway), these data suggest that ER
stress activation by compound 1 seems to be speciﬁc of the
IRE1-XBP1, and not a consequence of a general loss of the
Fig. 4 The eﬀect of compound 1 and NB-DNJ on the lactosylcer-
amide (LacCer) and ganglioside content of A549 carcinoma cells. The
data were normalized to the same number of cells (1  106 cells). The
content in pmol per 1  106 cells for the control was: 10  3; 554  43;
578  110; 1.3  0.1; 19  2 and 9  1 for LacCer, GM3, GM2, GD2,
GM1 and GD1 respectively. Results are referred to samples from cells
treated with vehicle for 48 h. Black bars: A549 cells treated with 1
(10 mM); empty bars: A549 cells treated with NB-DNJ (50 mM). The
diagram includes the ANOVA results for each treatment with respect
to control at a signiﬁcance level of: *p o 0.05; **p o 0.01.
Fig. 5 Relative amounts of gangliosides in melanoma A375 (black
bars) and glioma C6 (empty bars) cells treated with 1 (10 mM) for 96
and 48 h, respectively. Data are means  SD of two experiments
performed in duplicate. The diagram includes the ANOVA results for
each treatment with respect to control at a signiﬁcance level of:
*p o 0.05; **p o 0.01.
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ER homeostasis, that should induce ATF6 pathway too.
XBP1 has been related to lipogenesis.23 Conditional deletion
of XBP1 in the liver of mice reduces lipogenesis in the adult
liver. Recently, Goldﬁnger and coworkers24 have shown that
XBP1 increases de novo synthesis of ceramide. Considering the
results of our present work, we propose that at low concen-
trations (o25 mM), compound 1 reduces ceramide and other
glycolipids, but does not induce ER stress pathways and cell
death. At higher concentration of compound 1 (425 mM),
IRE1-XBP1 branch was induced, increasing ceramide
and other glycolipids at the same time. In this scenario, the
activation of IRE1-XBP1 branch could result in a feed-back
pathway, increasing ceramide and glycolipid accumulation
and ﬁnally inducing cell death, as observed in A549 cells
(Fig. 7).
2.5 Metabolism of 1. Synthesis and evaluation of two
galactosylated derivatives of 1
The extracts used for sphingolipidomics with A549 cells were
analyzed also for the presence of glycoside 1 and putative
metabolites. The presence of 1 was conﬁrmed based on
the accurate mass measurement with an error o5 ppm
(m/z calculated for C26H50NO6: 472.3638; found: 472.3631,
error 1.5 ppm) and its LC retention time, compared to that
of an authentic sample (Fig. 9). This observation indicated
that the synthetic glycolipid was eﬃciently taken up by the
cells. The presence of oleyl alcohol, that could derived from
hydrolysis of 1, was not detected in the analysis by LC-MS.
Nevertheless, in order to rule out the possibility that the
activity of 1 is due to a small fraction of hydrolysis product,
oleyl alcohol was tested as inhibitor of A549 cell division. The
IC50 value (4100 mM) was signiﬁcantly higher than that of 1
Fig. 6 Viable A549 cells without treatment (A) and after treatment with 30 and 50 mM compound 1 (B and C, respectively).
Fig. 7 Ceramide (Cer), sphingomyelin (SM), glucosylceramide
(GlcCer), lactosylceramide (LacCer) and gangliosides content in
A549 cells treated with 1 (10 and 30 mM). Data were normalized to
the same number of cells (1  106 cells). The content in pmol per 1 
106 cells for the control was: 214  43; 3127  277; 153  16; 10  3;
554  43 and 578  110 for Cer, SM, GlcCer, LacCer, GM3 and GM2
respectively. Data are means  SD of two experiments performed in
duplicate. The diagram includes the ANOVA results for each treat-
ment with respect to control at a signiﬁcance level of: *p o 0.05;
**p o 0.01.
Fig. 8 Compound 1 induced IRE1-XBP1 branch of the ER stress response pathway in C6 cells. A reporter was cotransfected for (A) the ATF6
pathway (ERSE-pGL3) or (B) the IRE1-XBP1 pathway (UPRE-pGL3), and a plasmid with the b-galactosidase gene as control for transfection
eﬃciency. Data are shown as fold induction respect to the control. Tunicamycin (Tm) and octyl 6-O-pentaerythrityl-N-acetyl-a-D-glucosaminide
(OPG) were used as positive and negative controls, respectively, for the reporters. Data are means  SD of three independent experiments
performed in triplicate. The diagram includes the ANOVA results for each treatment with respect to control at a signiﬁcance level of: *po 0.05;
**p o 0.01.
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and, therefore, the possible formation of oleyl alcohol could
not explain the observed inhibitory activity. A new compound
was also detected in the lipid extract of cells incubated with 1
that was not present in control samples. Based on its accurate
mass measurement (m/z calculated for C32H60NO11: 634.4166;
found 634.4164, error 0.5 ppm), its relative retention time
compared to that of 1, and relative retention times of
C16-LacCer and C16-GlcCer, this compound has been putatively
identiﬁed as an oleyl disaccharide derived from the glycosylation
of 1. We considered the possibility that this compound
resulted from galactosylation of 1 by catalysis of LacCer
synthase. Such a product could be, in addition to 1, an
inhibitor of ganglioside biosynthesis, competing with LacCer
for the GM3 synthase. To clarify this question we synthesized
two b-galactosylated derivatives of 1 (disaccharides 3 and 6,
Scheme 2) and tested their eﬀect on ganglioside content.
Comparison of LC retention time and exact mass (see below,
Table 1) allowed us to conﬁrm the identity of the meta-
bolite formed from glycosylation of 1 as the b-(1,4)-linked
disaccharide 6.
The disaccharides were synthesized in a short and straight-
forward manner from 1 using readily available galactose
peracetate as glycosyl donor (Scheme 2). Thus, reaction of
galactose peracetate with 1 gave regioselectively b-(1,6)-linked
disaccharide 2, which after O-deacetylation aﬀorded target 3.
For the synthesis of 6 a highly regioselective acetylation on
HO-6 of 1 was carried out by lipase-catalyzed reaction with
vinyl acetate in dioxane. The 6-O-acetylated derivative 4
was the only product isolated in 85% yield. Regioselective
galactosylation on HO-4 over HO-3 of 4 was obtained using
BF3OEt2 as promoter, to give 5 in 31% yield with b-conﬁgured
glycosidic bond. Deacetylation of 5 furnished unprotected
disaccharide 6. The position of the glycosidic bond in 5 was
determined from the NMR spectra of its acetylated derivative 7.
The 1H NMR spectrum of 7 contained a downﬁeld signal at
d 5.18 ppm (dd, J2,3 = 10.9, J3,4 = 8.9 Hz) for H-3, indicating
that acetylation occurred at HO-3 of 6. On the other hand, the
signal for H-4 appeared upﬁeld at d 3.79 ppm, conﬁrming that
glycosylation took place at O-4.
The eﬀect of compounds 3 and 6 (15 mM) on sphingolipid
and ganglioside content was evaluated in A549 cells. We
observed that both disaccharides were partially metabolized
and converted into 1 by hydrolysis of the interglycosidic bond
(Scheme 3). Compound 3, with the 1,6-linkage, was more
susceptible to hydrolysis than 6. We also detected in the
extract of cells treated with the disaccharides the presence
of two new compounds that based on their accurate mass
measurement and relative retention times were assigned to
neutral glycohexopyranosyl (Gly) and to sialyl (Sial) derivatives
of 3 and 6 (Table 1).
The analysis of sphingolipid content in A549 cells after
treatment with 3 and 6 showed minor changes in Cer and
SM levels with respect to the control. In the case of GlcCer,
the b-(1,4)-linked disaccharide induced an increase of almost
60% of this metabolite as compared to control, while the eﬀect
of the b-(1,6)-regioisomer was less intense (Fig. 10). Major
changes were observed in the levels of LacCer and gangliosides
(Fig. 10). The eﬀect on LacCer levels was more pronounced
with the disaccharides than with the monosaccharide 1. The
treatment with 3 and 6 caused a 2–3 fold increase in LacCer
content, the eﬀect of the 1,6-linked disaccharide was slightly
stronger than that of regioisomer 6. Interestingly, while the
Fig. 9 Metabolism of compound 1 in A549 cells. Selected ion
chromatograms generated by LC-MS of lipid extract of cells incubated
with 1 (10 mM) or vehicle (control). Traces correspond to compound 1
(retention time 3.31 min, m/z 472.3638), its glycosylated metabolite
(3.14 min, m/z 634.4166). For comparison purpose, traces of C16-
glucosylceramide (6.90 min, m/z 700.5728) and C16-lactosylceramide
(6.62 min, m/z 862.6255) are also shown.
Scheme 2 Synthesis of disaccharides 3 and 6: (a) penta-O-acetyl-b-D-
galactopyranose, BF3OEt2, CH2Cl2–CH3CN, 0 1C, 2 h; (b) NaOMe/
MeOH 0.1 M, rt, 1 h; (c) vinyl acetate, Novozym 435, dioxane, 37 1C,
12 h; (d) galactose peracetate, BF3OEt2, CH2Cl2, 0 1C, 6 h;
(e) NaOMe/MeOH 1 M, rt, 30 min; (f) Ac2O, py, rt, 4 h.
D
ow
nl
oa
de
d 
on
 0
4 
M
ay
 2
01
2
Pu
bl
ish
ed
 o
n 
05
 N
ov
em
be
r 2
01
0 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/C
0M
B0
012
5B
View Online
This journal is c The Royal Society of Chemistry 2011 Mol. BioSyst., 2011, 7, 129–138 135
amounts of monosialo-gangliosides GM1 and GM2 decreased
compared to control, the amount of the simple ganglioside
GM3 increased in treated cells with respect to control. The
latter eﬀect contrasted with the reduction in GM3 level
observed after treatment with 1. These results suggest that
while 1 may be acting at the step of GM3 formation, the
disaccharide derivatives should be interacting with enzymes
involved in further steps of the ganglioside biosynthetic path-
way. Overall, the results with 3 and 6 support the hypothesis
that this family of synthetic compounds alters tumoral
cell ganglioside metabolism, leading to signiﬁcant changes in
ganglioside content. In order to conﬁrm this hypothesis,
enzymatic assays with glycosyltransferases involved in early
steps of ganglioside biosynthesis will have to be done in future
studies.
Conclusion
It is interesting that a seemingly simple oleyl glycoside exhibits
a signiﬁcant antiproliferative activity in a variety of tumor cell
lines. In a recent patent25 describing the use of alkylated
iminosugars as anticancer agents, it was found that the
compounds bearing an oleyl substituent presented the most
potent activity. This ﬁnding together with our previous results,
in which 1 was the most potent antitumoral compound among
those of a series of glucosaminide derivatives, seem to indicate
that the activity of 1 as inhibitor of cancer cell growth was
likely due to the conjugation of the sugar with the oleyl chain.
In the present work, we have investigated the mode of action
of 1 under the hypothesis that it could be altering the
metabolism of lipids, as indicated in our previous 1H MAS
NMR study. We have now found that oleyl glycoside 1
at 10 mM downregulated the synthesis of fatty acids and
sphingolipids in A549 cells. In addition, glycoside 1 decreased
ganglioside content of human A549, rat C6 and human A375
cells. The intervention on cellular processes important for
tumor development may help to understand its antiproliferative
activity.
On the other hand, compound 1 at higher concentrations
(above 30 mM) caused drastic alterations in glycosphingolipid
metabolism, displaying cell metabolic proﬁles very diﬀerent
from those obtained at 10 mM concentration, and led to cell
death. Preliminary results seem to indicate that 1 at concen-
trations of 25–100 mM activates ER stress response pathways.
More precisely, compound 1 induced IRE1-XBP1 branch
pathway, but not ATF6 pathway. This induction could
explain the drastic changes observed in glycosphingolipid
metabolism since transcription factor XBP1 has been identiﬁed
as a regulator of lipogenesis.
Further work to conﬁrm the interaction of 1 with enzymes
involved in ganglioside metabolism and the activation of ER
stress response pathways is the aim of our future research.
3. Experimental
3.1 Chemistry
3.1.1 General methods. Chemicals were purchased puriss
p.A. from commercial suppliers or puriﬁed by standard
techniques. Thin-layer chromatography (TLC) was performed
on aluminium sheets 60 F254 Merck silica gel and compounds
were visualized by irradiation with UV light and/or by treat-
ment with a solution of Ce2MoO4 or 5% H2SO4 in EtOH,
Table 1 Detected compounds by UPLC-MS and proposed metabolites in A549 cells after treatment with disaccharides 3 and 6
rt/mina Exact massa (error in ppm) Amount (pmol/1  106 cell) Metabolite
3-treated cells 3.30 472.3638 (1.9) 2779  297 1
2.88 634.4166 (0.3) 1148  158 3
2.70 796.4694 (0.0) 19  3 Gly-3
2.50 925.5120 (0.8) 27  2 Sial-3
6-treated cells 3.30 472.3638 (0.6) 1458  231 1
3.15 634.4166 (1.3) 809  146 6
2.90 796.4694 (0.6) 31  11 Gly-6
2.80 925.5120 (3.0) 34  7 Sial-6
a As indicated by UPLC-MS.
Scheme 3 Metabolism of tested disaccharides 3 and 6 in A549 cells.
Fig. 10 Eﬀect of b-(1,6)- and b-(1,4)-linked disaccharides, 3 and 6
respectively, on sphingolipid and ganglioside content. The data were
normalized to the same number of cells (1  106 cells). The content in
pmol per 1 106 cells for the control was: 214 43; 3127 277; 153 16;
10  3; 554  43; 578  110 and 11.3  0.5 for Cer, SM, GlcCer,
LacCer, GM3, GM2 and GM1 respectively. These data are represen-
tative of three diﬀerent experiments performed by duplicate. The
diagram includes the ANOVA results for each treatment with respect
to control at a signiﬁcance level of: *p o 0.05; **p o 0.01.
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followed by heating. Flash column chromatography was
performed using thick walled columns, employing silica gel
(Merck 60: 0.040–0.063 mm). The eluent used is indicated, and
solvent ratios refer to volume. Melting points are not
corrected. Optical rotations were recorded on a Perkin Elmer
241 Polarimeter (l = 589 nm, 1 dm cell). 1H NMR spectra
were registered at 500, 400 or 300 MHz, and 13C NMR were
obtained at 125 or 100 MHz using CD3OD as solvent at room
temperature. Chemical shift values are reported in parts
per million (d). Coupling constant values (J) are reported in
hertz (Hz), and spin multiplicities are indicated by the
following symbol: s (singlet), d (doublet), t (triplet), q (quartet),
m (multiplet). Mass spectroscopy spectra were registered on a
hp series 1100 MSD spectrometer.
3.1.2 Oleyl 2-acetamido-6-O-(2,3,4,6-tetra-O-acetyl-b-D-
galactopyranosyl)-2-deoxy-a-D-glucopyranoside (2). To a solution
of 1 (360 mg, 0.77 mmol) in anhydrous CH2Cl2–CH3CN
(1 : 1, 40 ml), penta-O-acetyl-b-D-galactopyranose (300 mg,
0.77 mmol) was added and the mixture was cooled to 0 1C.
Then, BF3OEt2 (0.1 ml, 1.3 mmol) was added and the solution
was stirred at 0 1C under argon for 2 h. After this time, the
reaction mixture was treated with Et3N (0.2 ml), concentrated
in vacuo and the residue was puriﬁed by silica gel column
chromatography (EtOAc) to aﬀord 2 (183 mg, 30%) as a white
solid. mp: 67–69 1C; [a]D =+15.31 (C 0.7, MeOH);
1H NMR
(400 MHz, CD3OD): d 5.4–5.3 (m, 3H), 5.2–5.1 (m, 2H), 4.74
(d, 1H, J = 3.6 Hz), 4.67 (dd, 1H, J = 9.0, 4.9 Hz), 4.2–4.1
(m, 4H), 3.84 (dd, 1H, J = 10.7, 3.5 Hz), 3.8–3.6 (m, 4H),
3.4–3.3 (m, 1H), 3.3–3.2 (m, 1H), 2.13 (s, 3H), 2.1–1.9
(m, 16H), 1.5–1.4 (m, 2H), 1.4–1.2 (m, 22H), 0.89 (t, J =
6.7 Hz) ppm; 13C NMR (125 MHz, CD3OD): d 172.1, 170.6,
170.5, 170.05, 169.9, 129.4, 129.4, 101.3, 96.8, 71.3, 71.1, 70.1,
70.9, 70.3, 69.3, 69.0, 67.4, 67.3, 61.1, 54.0, 31.6, 29.5, 29.4, 29.3,
29.3, 29.2, 29.0, 29.0, 28.9, 28.9, 26.7, 26.7, 25.8, 22.3, 21.1, 20.6,
19.4, 19.1, 19.1, 19.1, 13.0 ppm; HRMS (ESI) m/z Anal. calcd.
for C40H68NO15: 802.4589, found 802.4589 (M + H)+.
3.1.3 Oleyl 2-acetamido-2-deoxy-6-O-(b-D-galactopyranosyl)-
a-D-glucopyranoside (3). 2 (140 mg, 0.17 mmol) was treated
with a 0.1 M solution of NaOMe in MeOH (3 ml), and the
solution was stirred at room temperature for 1 h. After this
time, the mixture was neutralized with Amberlite IR-120
(hydrogen form). The Amberlite was ﬁltered, the solvent was
removed in vacuo and the residue was puriﬁed by silica gel
column chromatography (EtOAc–MeOH 5 : 1- 2 : 1) to give
3 (94 mg, 87%) as a white solid. mp: 172–178 1C; [a]D =
+34.41 (C 2.9, MeOH); 1H NMR (400 MHz, CD3OD):
d: 5.4–5.3 (m, 2H), 4.77 (d, 1H, J = 3.6 Hz), 4.30 (d, 1H,
J = 7.6 Hz), 4.13 (dd, 1H, J = 10.9, 2.0 Hz), 3.89 (dd, 1H,
J = 10.7, 3.6 Hz), 3.9–3.6 (m, 7H), 3.6–3.4 (m, 4H), 3.4–3.3
(m,1H), 2.0–2.0 (m,4H), 1.98 (s, 3H), 1.6–1.5 (m, 2H), 1.4–1.3
(m, 22H), 0.90 (t, 3H, J= 6.9 Hz) ppm; 13C NMR (100 MHz,
CD3OD): d 173.6, 130.8, 130.8, 105.3, 98.5, 76.7, 75.0, 72.7,
72.6, 72.5, 72.2, 70.3, 69.7, 69.1, 62.5, 55.4, 30.9, 30.8, 30.8,
30.7, 30.6, 30.6, 30.5, 30.4, 30.4, 30.3, 28.2, 28.1, 27.3, 23.8,
22.6, 14.5 ppm; HRMS (ESI) m/z Anal. calcd. for
C32H60NO11: 634.4166, found: 634.4158 (M + H)+.
3.1.4 Oleyl 2-acetamido-6-O-acetyl-2-deoxy-a-D-gluco-
pyranoside (4). 1 (70.3 mg, 0.15 mmol) was dissolved in dioxane
(3 ml) and Novozym 435 lipase (30 mg, 10 mg ml1) was added.
Then, the mixture was treated with vinyl acetate (0.15 mL,
1.6 mmol) and was stirred at 37 1C in an orbitalic shaker
(150 rpm) for 12 h. The lipase was ﬁltered, the solvent was
removed in vacuo and the residue was puriﬁed by silica gel
column chromatography (EtOAc) to give 4 (64.9 mg, 85%) as a
white solid. mp: 110–111 1C; [a]D = +89.21 (C 0.5, MeOH);
1H NMR (400 MHz, CD3OD): d: 5.4–5.3 (m, 2H), 4.76 (d, 1H,
J = 3.6 Hz), 4.37 (dd, 1H, J = 11.8, 2.1 Hz), 4.20 (dd, 1H,
J = 11.8, 6.0 Hz), 3.88 (dd, 1H, J = 10.7, 3.6 Hz), 3.77 (ddd,
1H, J= 9.9, 6.0, 2.0 Hz), 3.7–3.6 (m, 2H), 3.5–3.3 (m, 2H, H-4),
2.2–2.0 (m, 7H), 1.98 (s, 3H), 1.7–1.5 (m, 2H), 1.4–1.3 (m, 22H),
0.90 (t, 3H, J = 6.8 Hz) ppm; 13C NMR (100 MHz, CD3OD):
d 173.6, 172.7, 130.9, 130.9, 98.6, 72.7, 72.5, 71.3, 69.2, 65.0,
55.5, 33.7, 33.2, 31.0, 30.9, 30.9, 30.8, 30.7, 30.6, 30.6, 30.6, 30.5,
30.5, 30.3, 28.3, 28.2, 27.4, 23.8, 22.7, 20.9, 14.6 ppm; HRMS
(ESI)m/zAnal. calcd. for C28H52NO7: 514.3743, found:: 514.3745
(M + H)+.
3.1.5 Oleyl 2-acetamido-6-O-acetyl-4-O-(2,3,4,6-tetra-O-
acetyl-b-D-galactopyranosyl)-2-deoxy-a-D-glucopyranoside (5).
4 (622 mg, 1.21 mmol) was dissolved in anhydrous CH2Cl2
(36 ml) and penta-O-acetyl-b-D-galactopyranose (946 mg,
2.42 mmol) was added. The mixture was cooled at 0 1C and
then treated with BF3OEt2 (1.26 ml, 10.9 mmol) and stirred at
that temperature for 6 h. After this time, the reaction mixture
was treated with Et3N (1.5 ml), concentrated in vacuo and the
residue was puriﬁed by silica gel column chromatography
(Hexane-EtOAc, 1 : 1 - 0 : 1) to give 5 (319 mg, 31%) as a
white solid. mp: 53–55 1C; [a]D = +60.91 (C 3.0, MeOH);
1H NMR (400MHz, CD3OD): d: 5.40 (dd, 1H, J=6.1, 1.6 Hz),
5.4–5.3 (m, 2H), 5.2–5.1 (m, 2H), 4.81 (d, 1H, J = 7.7 Hz),
4.77 (d, 1H, J = 3.6 Hz), 4.34 (dd, 1H, J = 11.8, 1.9 Hz),
4.3–4.2 (m, 1H), 4.2–4.1 (m, 2H), 4.09 (dd, 1H, J=11.8, 5.9 Hz),
3.92 (dd, 1H, J = 10.7, 3.6 Hz), 3.9–3.7 (m, 2H),
3.66 (dt, 1H, J = 9.9, 6.6 Hz), 3.6–3.5 (m, 1H), 3.41 (dt, 1H,
J=9.9, 6.3 Hz), 2.21 (s, 3H), 2.1–1.9 (m, 19 H), 1.7–1.5 (m, 2H),
1.4–1.3 (m, 22H), 0.90 (t, 3H, J = 6.9 Hz) ppm; 13C NMR
(100 MHz, CD3OD): d 173.4, 172.5, 172.2, 171.8, 171.3, 171.3,
130.8, 130.8, 102.5, 98.1, 83.4, 72.4, 72.4, 70.8, 70.5, 69.3, 69.1,
68.8, 64.3, 62.8, 54.9, 33.6, 33.1, 30.9, 30.8, 30.8, 30.7, 30.6, 30.5,
30.5, 30.4, 30.4, 30.2, 28.2, 28.1, 27.3, 23.7, 22.5, 20.9, 20.7, 20.6,
20.5, 20.4, 14.5 ppm; HRMS (ESI) m/z Anal. calcd. for
C42H70NO16: 844.4689, found: 844.4699 (M + H)+.
3.1.6 Oleyl 2-acetamido-2-deoxy-4-O-(b-D-galactopyrano-
syl-a-D-glucopyranoside (6). 5 (115 mg, 0.14 mmol) was dis-
solved in 20 mL MeOH and treated with a 1 M solution of
NaOMe (2 ml). The reaction mixture was stirred at room
temperature for 30 min. After this time, the mixture was
neutralized with Amberlite IR-120 (hydrogen form). The
Amberlite was ﬁltered, the solvent was removed in vacuo and
the residue was puriﬁed by silica gel column chromatography
(EtOAc–MeOH 5 : 1- 2 : 1) to give 6 (83.9 mg, 97%) as a white
solid. mp: 162–169 1C; [a]D = +67.51 (C 1, MeOH);
1H NMR
(400MHz, CD3OD, COSY): d: 5.4–5.3 (m, 2H), 4.79 (d, 1H, J=
3.5 Hz), 4.37 (d, 1H, J = 7.4 Hz), 3.91 (dd, 1H, J = 10.8,
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3.6 Hz), 3.9–3.8 (m, 3H), 3.8–3.5 (m, 8H), 3.49 (dd, 1H, J= 9.7,
3.2 Hz), 3.4–3.3 (m, 1H), 2.1–2.0 (m, 4H), 1.98 (s, 3H), 1.6–1.5
(m, 2H), 1.5–1.25 (m, 22H), 0.90 (t, 3H, J = 6.9 Hz) ppm;
13CNMR (100MHz, CD3OD): d 172.3, 129.7, 129.6, 103.9, 97.0,
80.1, 75.9, 73.6, 71.4, 71.0, 69.8, 69.1, 67.9, 61.3, 60.7, 53.9, 31.9,
29.70, 29.6, 29.6, 29.5, 29.4, 29.4, 29.3, 29.2, 29.1, 27.0, 26.9, 26.1,
22.6, 21.4, 13.3 ppm; HRMS (ESI) m/z Anal. calcd. for
C32H60NO11: 634.4166, found: 634.4166 (M + H)+.
3.1.7 Oleyl 2-acetamido-3,6-di-O-acetyl-4-O-(2,3,4,6-tetra-
O-acetyl-b-D-galactopyranosyl)-2-deoxy-a-D-glucopyranoside (7).
5 (19 mg, 0.02 mmol) was dissolved in pyridine (0.5 ml) and
acetic anhydride (0.5 ml) was added. The reaction mixture was
stirred at room temperature for 4 h. After this time, the solvent
was evaporated in vacuo and the crude was puriﬁed by silica gel
column chromatography (EtOAc–hexane 2 : 1) to give 7 (19.5 mg,
98%) as a white solid. 1H NMR (500 MHz, CD3OD, COSY):
d: 5.4–5.3 (m, 3H), 5.18 (dd, 1H, J=10.9, 8.9 Hz), 5.11 (dd, 1H,
J= 10.4, 3.5 Hz), 5.02 (dd, 1H, J= 10.4, 7.9 Hz), 4.74 (d, 1H,
J = 3.7 Hz), 4.69 (d, 1H, J = 7.9 Hz), 4.47 (dd, 1H, J = 11.8,
2.0 Hz), 4.2–4.1 (m, 5H), 3.9–3.8 (m, 1H), 3.79 (dd, 1H,
J = 10.0, 9.0 Hz), 3.68 (dt, 1H, J = 9.8, 6.9 Hz), 3.5–3.4
(m, 1H), 2.2–2.1 (m, 6H), 2.1–2.0 (s, 3H), 2.0–1.9 (m, 16H),
1.7–1.6 (m, 2H), 1.5–1.2 (m, 22H), 0.93 (t, 3H, J=6.9 Hz) ppm,
13C NMR (126 MHz, CD3OD): d 173.5, 172.3, 172.2, 172.0,
171.9, 171.4, 171.1, 130.9, 130.8, 102.1, 98.3, 78.1, 72.7, 72.5,
71.7, 70.8, 70.0, 69.5, 68.6, 63.9, 62.3, 53.2, 33.0, 30.9, 30.8, 30.8,
30.7, 30.6, 30.6, 30.5, 30.4, 30.4, 30.3, 30.3, 28.1, 28.1, 27.3, 24.2,
23.7, 22.4, 21.2, 20.7, 20.7, 20.6, 20.5, 14.4 ppm.
3.2 Analytical experiments
3.2.1 Chemicals. Sphingolipids were from Avanti Polar
Lipids. 6-(7-Nitrobenzofurazan-4-ylamino)hexanoic acid
(C6NBD), 1-hydroxybenzotriazole (HOBT), N-ethyl-N0-(3-di-
methylaminopropyl)carbodiimide (EDC), NB-DNJ, oleic alcohol
and oleic acid were purchased from Sigma-Aldrich. Fluores-
cent Ceramide-C6NBD was obtained by acylation of sphingosine
with C6NBD using standard procedures. Purity was assessed
by HPLC and accurate mass measurement. HRMS calcd:
C30H49N5O6: 575.3683; found: 575.3688. Compound 1 was
synthesized as previously described.17
3.2.2 Liquid chromatography-mass spectrometry analysis
of sphingolipids. A549 cells (2.5  105 cells mL1) were seeded
in 1 mL of medium with 10% FBS in a 6-well plates. Twenty-
four hours later, media were replaced with fresh medium
containing test compound or vehicle solvent and cultured for
48 h at 37 1C/5% CO2. Then, cells were washed in PBS,
collected by brief trypsinization and transferred to glass vials.
An aliquot of the cells was taken for cell counting, using a
Countess automatic cell counter. Sphingolipid extracts, spiked
with internal standards, were prepared as described26 and
analysed by liquid chromatography–mass spectrometry using
a Waters Aquity UPLC system connected to a Waters LCT
Premier orthogonal accelerated time of ﬂight mass spectrometer
(Waters, Millford, MA), operated in positive electrospray
ionisation mode in the conditions previously reported.27
3.2.3 C6 and A375 ganglioside analysis. C6 and A375 cells
(2  105 cells cm2) were seeded in 30 mL of DMEM medium
with 10% FBS in plastic ﬂasks and allowed to attach for 6 h.
After the cells were attached to the substrate, the medium was
changed to DMEM without serum. Twenty-four hours later,
media were replaced with fresh medium containing compound
1 (10 mM) and cultured for 48 h (A375) or 96 h (C6) at 37 1C/
5% CO2. Then, cells were washed twice with 15 mM PBS
(140 mM NaCl, pH = 7.4), collected by brief trypsinization
and pelleted by centrifugation at 2000 g for 5 min at 4 1C.
Then, cells were lyophilized, ﬁnely powdered and extracted
twice with chloroform–methanol (1 : 1, 2.5 mL) to obtain the
total lipid extract. The combined extracts were cooled at 4 1C
overnight, and centrifuged to remove insoluble material. Total
lipid extract was dried completely under reduced pressure and
gangliosides were isolated by extracting with diisopropyl
ether-1-butanol (6 : 4) and 0.1% aqueous NaCl (1 mL) and
subsequent ﬁltration on Sephadex G-50 gel.13 Gangliosides
were lyophilized and analyzed by HPLC. HPLC analysis. All
analyses were performed using a Jasco Pu-2089 Plus pump
equipped with an ultraviolet Jasco UV-2075 Plus detector and
a 20 mL Rheodyne injector. Data acquisition and processing
were accomplished with the Jasco ChromPass Chromatography
Data System 1.8.6.1 software. A normal phase Kromasil-NH2
(5 mm, 4.6  250 mm) column was used as stationary
phase. Ganglioside separation was carried out with a mobile
phase made with the following gradient mixture: solvent A,
acetonitrile–5 mM sodium phosphate buﬀer, pH 5.6 (83 : 17);
solvent B, acetonitrile-20 mM sodium phosphate buﬀer, pH
5.6 (50 : 50). The gradient elution program was the same as
described earlier.28 The ﬂow rate was 1.0 mL min1 and the
elution proﬁle was monitored by recording the UV absorbance
at 215 nm. Retention times of individual gangliosides were
compared with the retention times of commercially available
pure gangliosides. The isolated gangliosides were collected
into fractions for MALDI-TOF mass spectrometric analysis.
3.3 Enzymatic activity
3.3.1 Cells and cultures. Human alveolar epithelial A549,
rat glioma C6 cells and human melanoma A375 cells were
obtained from the American Type Culture Collection (ATCC)
and grown in medium HAM F12 (A549) and DMEM (C6 and
A375) with glutamine medium supplemented with 10% foetal
bovine serum (FBS). Cell proliferation assays were performed
as described.27 The number of viable and dead cells was
determined by Trypan Blue staining and using a Countesss
Cell Counter (Invitrogen), following the manufacturer’s
recommendations.
3.3.2 Glucosylceramide and sphingomyelin synthase activity
(A549). A549 cells cultured as described above were washed
with sodium phosphate (PBS) (10 mM, 137 mMNaCl, pH= 7.4)
and collected by brief trypsinization. The cells were then washed
twice with PBS and resuspended in 50 mM TRIS-HCl,
pH = 7.4, 10 mM MgCl2 and lysed. The cell lysate (100 mL)
was incubated with inhibitors for 10 min at 37 1C and NAD
(25 mL, 16 mM in 50 mM TRIS-HCl buﬀer, pH= 7.4, 10 mM
MgCl2), BSA/Cer-C6-NBD complex (52 mL, 1 : 1, 20 mM in
50 mM TRIS-HCl buﬀer, pH = 7.4, 10 mM MgCl2) and
UDP-Glucose (25 mL, 2 mM in 50 mM TRIS-HCl buﬀer,
pH = 7.4, 10 mM MgCl2) were added and incubations were
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prolonged for 35 min. The reaction was stopped by adding
methanol (800 mL) to each reaction mixture and centrifuging
at 13000 g for 3 min. HPLC coupled to a ﬂuorescence detector
was used to measure the glucosylceramide synthase and
sphingomyelin synthase activities by injecting 25 mL of the
supernatant. HPLC analysis: 15 cm reverse-phase C18
column, ﬂow rate 1 mL min1, column temperature 25 1C,
mobile phase 25% H2O-75% acetonitrile, both with a 0.1%
triﬂuoroacetic acid. Fluorescence detector, excitation at
470 nm and emission at 530 nm. Calibration curves showed
linear response in the concentration ranges of the analyses.
3.4 Luciferase reporter assays in C6 glioma cells
To evaluate the activation of IRE1-XBP1 and ATF6 pathways
by compound 1 treatment, we used a UPRE luciferase reporter
(5xUPRE-pGL3) and ERSE-pGL3 reporter, respectively.
C6 glioma cells (2  104 cells per well) were cotransfected
with 5  UPRE-pGL3 or ERSE-pGL3 constructs, and a
b-galactosidase construct, as a control for transfection
eﬃciency. As a transfection reagent, we used Fugene HD
(Roche, Mannheim, Germany) according to the manufacturer’s
protocol. After 48 h of treatment, the cells were washed with
PBS, passive lysis buﬀer (Promega) was added to each well and
the samples were stored at 80 1C until use. Luciferase activity
was measured in a Sirius luminometer (Berthold detection
systems, Pforzheim, Germany). We used a Multiskan Ascent
(Thermo Electron Corporation, Shanghai, China) to detect
b-galactosidase activity in the samples.
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